Evidence map›Paper›PMID 30986252›Full record

ArticlePLoS neglected tropical diseases2019

Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?

Lance Turtle, Hannah E Brindle, W William Schluter, Brian Faragher, Ajit Rayamajhi, Rajendra Bohara, Santosh Gurung, Geeta Shakya, Sutee Yoksan, Sameer Dixit and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

Lance TurtleInstitute of Infection and Global Health and National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, United Kingdom.ORCID 0000-0002-0778-1693
Hannah E BrindleInstitute of Infection and Global Health and National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, United Kingdom.
W William SchluterWorld Health Organization, Kathmandu, Nepal.
Brian FaragherLiverpool School of Tropical Medicine, Liverpool, United Kingdom.
Ajit RayamajhiKanti Children's Hospital, Maharajgunj, Kathmandu, Nepal.
Rajendra BoharaWorld Health Organization, Kathmandu, Nepal.
Santosh GurungWorld Health Organization, Kathmandu, Nepal.
Geeta ShakyaNational Public Health Laboratory, Teku, Kathmandu, Nepal.
Sutee YoksanInstitute of Molecular Biosciences, Mahidol University and Translational Research Unit, Chulabhorn Research Institute, Bangkok, Thailand.
Sameer DixitCenter for Molecular Dynamics Nepal, Thapathali, Kathmandu, Nepal.
Rajesh RajbhandariCenter for Molecular Dynamics Nepal, Thapathali, Kathmandu, Nepal.
Bimal PaudelNational Public Health Laboratory, Teku, Kathmandu, Nepal.
Shailaja AdhikariNational Public Health Laboratory, Teku, Kathmandu, Nepal.
Tom SolomonInstitute of Infection and Global Health and National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, United Kingdom.
Mike J GriffithsInstitute of Infection and Global Health and National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, United Kingdom.
University of Liverpool · GBMinistry of Health and Population · NPNational Public Health Laboratory · NPCenter for Molecular Dynamics - Nepal · NPKanti Children's Hospital · NPLiverpool School of Tropical Medicine · GBMahidol University · TH

Funding

Department of Health EME/12/205/28Department of Health IS-HPU-1112-10117Department of Health RP-PG-0108-10048Medical Research Council G116/194Medical Research Council MC_PC_15096Wellcome TrustWellcome Trust 102465/Z/13/AWellcome Trust 205228/Z/16/ZWorld Health Organization 001
6 · The paper itself

Abstract

The live attenuated Japanese encephalitis (JE) vaccine SA14-14-2 has been used in Nepal for catch-up campaigns and is now included in the routine immunisation schedule. Previous studies have shown good vaccine efficacy after one dose in districts with a high incidence of JE. The first well-documented dengue outbreak occurred in Nepal in 2006 with ongoing cases now thought to be secondary to migration from India. Previous infection with dengue virus (DENV) partially protects against JE and might also influence serum neutralising antibody titres against JEV. This study aimed to determine whether serum anti-JEV neutralisation titres are: 1. maintained over time since vaccination, 2. vary with historic local JE incidence, and 3. are associated with DENV neutralising antibody levels. We conducted a cross-sectional study in three districts of Nepal: Banke, Rupandehi and Udayapur. Udayapur district had been vaccinated against JE most recently (2009), but had been the focus of only one campaign, compared with two in Banke and three in Rupandehi. Participants answered a short questionnaire and serum was assayed for anti-JEV and anti-DENV IgM and IgG (by ELISA) and 50% plaque reduction neutralisation titres (PRNT50) against JEV and DENV serotypes 1-4. A titre of ≥1:10 was considered seropositive to the respective virus. JEV neutralising antibody seroprevalence (PRNT50 ≥ 1:10) was 81% in Banke and Rupandehi, but only 41% in Udayapur, despite this district being vaccinated more recently. Sensitivity of ELISA for both anti-JEV and anti-DENV antibodies was low compared with PRNT50. DENV neutralising antibody correlated with the JEV PRNT50 ≥1:10, though the effect was modest. IgM (indicating recent infection) against both viruses was detected in a small number of participants. We also show that DENV IgM is present in Nepali subjects who have not travelled to India, suggesting that DENV may have become established in Nepal. We therefore propose that further JE vaccine campaigns should be considered in Udayapur district, and similar areas that have had fewer vaccination campaigns.

Indexed as

Immunization ProgramsAdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralCross-Sectional StudiesDengue VirusEncephalitis, JapaneseEncephalitis Virus, JapaneseEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GImmunoglobulin MJapanese Encephalitis VaccinesAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GImmunoglobulin MJapanese Encephalitis Vaccines

Identifiers

PMID30986252
PMCPMC6483279
OpenAlexW2937046010

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.